Section One: Introduction

1.1 Research Background and Significance

The United States healthcare system faces a paradoxical and devastating dual crisis in prescription drug management: unaffordable life-sustaining medications for millions of ordinary citizens alongside massive, unnecessary waste of viable prescription drugs. On a monthly basis, countless American households are forced to make an unthinkable trade-off—purchasing essential chronic illness medications or covering basic living expenses including rent, groceries, utility services, and childcare costs. This societal dilemma has evolved from an individual financial hardship into a widespread public health and systemic governance crisis that plagues the entire U.S. healthcare industry.
Practically, this research addresses a critical real-world conflict between pharmaceutical resource scarcity and excessive waste. Resolving this issue can reduce preventable illnesses, permanent physical damage, and deaths caused by medication rationing or abandonment, while cutting pharmaceutical pollution from medical waste and easing the financial burden on vulnerable families. Theoretically, this study fills the existing research gap that separates drug pricing regulation research and medical waste management research. Most prior studies analyze drug affordability or medical waste in isolation, while this article integrates the two interconnected systemic flaws, supplementing a holistic analytical framework for U.S. pharmaceutical system optimization.

1.2 Core Concept Definitions

Prescription drug access crisis: A systemic public health issue in the U.S. where working-class families, elderly citizens, and disabled individuals cannot afford medically necessary prescription drugs due to exorbitant drug prices, insurance coverage gaps, high deductibles, and insufficient low-income assistance programs, leading to delayed or abandoned treatment.
Surplus prescription medical waste: Refers to unopened, unexpired, safe, and fully functional prescription medications discarded by U.S. hospitals, long-term care facilities, pharmacies, and individual patients. This waste stems from outdated legal restrictions and industry norms that prohibit medication redistribution, rather than product quality issues.
This discussion strictly focuses on non-controlled, sealed, unexpired prescription drug redistribution and systemic pharmaceutical policy reform. It excludes illegal drug resale, expired medication reuse, and controlled substance circulation to ensure the safety and legality of the research scope.

1.3 Current Research Status, Domestic and International

Internationally, developed economies such as those in the European Union have established unified drug price regulation mechanisms and standardized medical drug recycling systems, effectively balancing drug accessibility and resource utilization. In contrast, U.S. pharmaceutical research has long focused on single-dimensional optimization. Early studies centered on pharmaceutical market pricing mechanisms, criticizing the lack of federal price regulation as the core cause of unaffordable drugs. Subsequent research gradually addressed medical waste problems, exploring hazardous waste disposal standards for unused medications.
However, mainstream U.S. research and practical practices have long ignored the internal correlation between drug pricing crises and pharmaceutical waste crises. Existing policies and academic proposals either focus solely on capping pharmaceutical enterprise profits or solely on improving medical waste disposal efficiency, lacking integrated solutions. Additionally, many scholars hold biased views that medication redistribution carries inherent safety risks, leading to slow progress in safe drug recycling policy promotion and insufficient practical case research on nonprofit drug redistribution models.

1.4 Framework and Core Objectives

This article adopts a problem-solution research framework. It first sorts out the dual dilemmas of U.S. prescription drug inaccessibility and pharmaceutical waste, conducts in-depth analysis of the root systemic causes, draws on the practical experience of the nonprofit organization SIRUM’s drug redistribution model, proposes targeted multi-level solutions, and formulates supporting guarantee measures for policy and industry implementation.
The core research questions of this article are: What are the essential systemic flaws leading to the coexistence of U.S. prescription drug inaccessibility and massive medical waste? How can standardized, safe drug redistribution models alleviate immediate public health and financial pressure? What long-term policy reforms can fundamentally resolve this dual crisis?
Readers will gain three key takeaways: a clear understanding of the interconnected nature of America’s pharmaceutical affordability and waste crises, practical operational logic of safe surplus medication redistribution, and a complete set of short-term and long-term optimization paths for the U.S. prescription drug system.

Section Two: Main Body (Problem-Solution Module)

2D.1 Overview of Main Problems

The U.S. prescription drug system currently suffers from two mutually reinforcing core problems, forming a vicious cycle that harms public health and wastes social resources. First, the widespread unaffordability of essential prescription drugs triggers severe public health risks. Statistical surveys show that one in four American adults adopts cost-cutting measures such as skipping medication doses, splitting pills, or completely abandoning prescribed treatment. This behavior directly leads to a surge in avoidable hospitalizations, permanent organ damage, and preventable deaths, while increasing the overall burden on the U.S. public healthcare system.
Second, large-scale valid pharmaceutical resources are wasted annually. U.S. medical institutions, pharmacies, and households discard billions of dollars’ worth of unopened, unexpired, and safe prescription medications including oral pills, topical creams, inhalers, and injectable drugs every year. These usable medical resources are uniformly disposed of as hazardous waste, polluting landfills and water resources, and forming a stark contrast with the public’s lack of access to essential medications. The coexistence of resource shortage and massive waste has become a prominent paradox of the U.S. healthcare system.

2D.2 In-Depth Root Cause Analysis

The dual crisis stems from two overlapping and flawed systemic mechanisms, rather than isolated individual or institutional errors. On the one hand, the lack of federal drug price regulation leads to skyrocketing pharmaceutical pricing. U.S. pharmaceutical manufacturers have almost no upper limit constraints on pricing life-saving drugs, allowing them to set exorbitant prices for chronic disease and essential medications. Compounded by imperfect commercial insurance systems—including widespread coverage gaps, high personal deductibles, and limited low-income pharmaceutical assistance programs—vulnerable groups such as low-income working families, elderly people, and disabled individuals are trapped between financial collapse and deteriorating health conditions.
On the other hand, outdated legal provisions and rigid industry norms cause systematic pharmaceutical waste. Current U.S. laws and traditional industry practices strictly prohibit the secondary circulation and reuse of prescription medications, even for sealed and unexpired products. This one-size-fits-all management mechanism ignores the safety and availability of surplus medications, forcing medical institutions and pharmacies to discard valid resources to comply with regulations. The disconnect between pricing regulation loopholes and medication recycling restrictions ultimately creates the abnormal phenomenon where millions cannot afford drugs while billions of dollars of medications are wasted.

2D.3 Reference to Advanced Experience

The nonprofit organization SIRUM provides a mature, verifiable practical experience for resolving the U.S. pharmaceutical dual crisis. Founded to break the deadlock between drug inaccessibility and waste, SIRUM has built a standardized, regulated, and safe surplus medication redistribution system. The organization cooperates with nursing homes, professional pharmacies, and individual patients nationwide to collect sealed and unopened surplus prescription drugs, strictly verifies product safety and expiration dates through professional inspection procedures, and delivers qualified medications to eligible low-income families at zero or near-zero cost.
Over ten years of operation, SIRUM has redistributed tens of millions of dollars’ worth of valid prescription medications, effectively curbing the phenomenon of medication rationing and abandonment among low-income groups and preventing thousands of avoidable health damages. Its five-year expansion plan aims to realize the recycling of nearly one billion dollars in surplus medications across the country. More importantly, SIRUM has pioneered state-level regulatory frameworks for prescription drug recycling, eliminating potential safety risks through standardized inspection protocols and providing a legal and operational template for nationwide promotion.

2D.4 Targeted Solutions and Suggestions

To resolve both immediate dilemmas and fundamental systemic flaws, this article proposes a combination of short-term emergency solutions and long-term institutional reforms. First, promote nationwide safe prescription medication recycling. Popularize the standardized operating model pioneered by SIRUM in all U.S. states, unify drug collection, safety verification, and distribution processes, and break legal and industry barriers to surplus medication reuse. This can immediately reduce pharmaceutical waste and provide affordable medication support for low-income groups.
Second, establish federal prescription drug price control mechanisms. Introduce unified national price regulation for life-saving and chronic disease prescription drugs to curb arbitrary high pricing by pharmaceutical manufacturers, fundamentally reducing the economic pressure of medication purchase on ordinary families.
Third, optimize the U.S. pharmaceutical assistance system for low-income populations. Fill insurance coverage gaps, appropriately reduce medical deductibles for vulnerable groups, and expand the coverage and subsidy intensity of low-income medication assistance programs to ensure basic medication access for disadvantaged groups.

2D.5 Safeguard Measures for Implementation

First, build unified national safety supervision standards for drug recycling. Formulate unified industry specifications for donated drug access, inspection, transportation, and distribution at the federal level, taking SIRUM’s mature inspection protocols as the benchmark to completely eliminate drug safety risks and dispel public and industry concerns about redistribution safety.
Second, improve cross-state policy coordination mechanisms. Accelerate the promotion of standardized drug recycling regulatory frameworks in all U.S. states, unify legal access pathways for surplus medication recycling nationwide, and avoid regional policy differences restricting resource circulation.
Third, establish a long-term dynamic monitoring mechanism. Track the operating effect of drug price control policies and medication recycling systems, regularly count medication waste reduction data, low-income medication accessibility improvement data, and public health indicator changes, and dynamically adjust policy details to ensure long-term effective operation of the system.

Section Three: Application and Implications

3.1 Practical Application Scenarios

The dual-crisis solution system proposed in this article is applicable to multiple scenarios in the U.S. healthcare industry and social governance. For medical and pharmaceutical institutions, hospitals and long-term care facilities can adopt standardized drug recycling processes to reduce institutional medical waste and fulfill social responsibility; community pharmacies can participate in drug collection and distribution networks to expand public service capabilities beyond commercial sales.
For social welfare organizations and nonprofit groups, the SIRUM model can be replicated nationwide to build regional medication redistribution platforms, providing targeted medical assistance for low-income families, disabled groups, and elderly residents. For government regulatory departments, the policy combination of price regulation and recycling legalization can be applied to national healthcare system reform, optimizing the overall allocation efficiency of pharmaceutical resources. For individual households, standardized drug recycling channels can help rationalize idle family medications while obtaining affordable essential drugs.

3.2 Common Misconceptions and How to Avoid Them

The most widespread misconception in industry and public cognition is that prescription drug redistribution inevitably carries safety risks. Many critics oppose medication recycling based on vague concerns about drug quality and circulation safety. In fact, qualified surplus drug redistribution strictly requires factory-sealed packaging, unexpired validity, and unaltered drug properties, with multiple professional safety inspections before redistribution. The public should distinguish between informal second-hand drug transactions and standardized institutional recycling systems to avoid blanket denial of legitimate safe redistribution mechanisms.
Another common implementation mistake is focusing only on waste reduction while ignoring fundamental price reform. Some regional pilot projects only promote drug recycling as a waste management measure, failing to cooperate with drug price regulation and assistance policy optimization, resulting in only temporary relief of partial problems and inability to resolve the root affordability crisis. Practitioners must adhere to the combination of resource recycling and institutional reform to achieve sustainable problem resolution.

3.3 Key Insights for Readers and Practitioners

This research brings two core cognitive shifts: first, the U.S. prescription drug crisis is not a single economic or public health problem, but a systemic governance problem formed by the superposition of pricing regulation failure and resource management failure; second, pharmaceutical resource conservation and public health equity are mutually compatible goals rather than conflicting demands.
For industry practitioners and policy makers, the actionable recommendation is to adopt a dual-governance idea of "short-term waste reuse + long-term institutional reform". In the short term, quickly promote standardized drug recycling to alleviate public pressure; in the long term, consolidate the system foundation through price control and policy optimization. For long-term industry development, the pharmaceutical system should shift from a profit-oriented single development model to a balanced model of commercial development and public welfare security.

Section Four: Summary and Outlook

4.1 Summary of Core Viewpoints

The United States is trapped in a unique dual crisis of unaffordable essential prescription drugs and massive valid pharmaceutical waste, caused by imperfect federal drug price regulation and outdated medication resource management systems. The nonprofit drug redistribution model represented by SIRUM has proven effective in alleviating immediate public health and financial pressure through standardized and safe resource recycling. Resolving the dual crisis requires both short-term promotion of nationwide safe medication recycling and long-term institutional reforms including drug price control and assistance system expansion. Ensuring affordable prescription drug access is a basic public health right, which is crucial for optimizing the U.S. healthcare system and promoting social equity.

4.2 Future Development Trends and Outlook

In the future, U.S. pharmaceutical governance will gradually move from fragmented single-point management to integrated systemic governance. Safe prescription drug recycling will achieve full nationwide legalization and standardized popularization, becoming an important part of U.S. medical resource conservation. Federal drug price regulation mechanisms will be further improved to curb excessive profiteering in the pharmaceutical industry and narrow the medication affordability gap among different income groups.
At the same time, emerging challenges will emerge, including cross-state unified supervision of drug recycling, dynamic balance between pharmaceutical enterprise innovation incentives and price control, and precise matching of surplus medications and low-income demand. Future research can further explore intelligent drug matching systems, cross-regional pharmaceutical resource scheduling mechanisms, and quantitative evaluation models of pharmaceutical policy equity, to continuously optimize the sustainable development of the U.S. prescription drug system.

Section Five: References

1. SIRUM Official Website. Surplus Medication Redistribution Impact Report (2010–2020). https://www.sirum.org
2. Kiah Williams. TED Talk Transcript: You Shouldn’t Have to Choose Between Filling Your Prescriptions and Paying Bills. 2024
3. U.S. Centers for Disease Control and Prevention. National Survey on Prescription Drug Non-Adherence Statistics. 2023

Learning Encouragement Note: Exploring systemic healthcare contradictions helps us understand the balance between market profit and public welfare, and continuous in-depth research on pharmaceutical policy optimization can drive more equitable and sustainable healthcare development.